The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

Movement Disorders

Volumn 29, Issue 8, 2014, Pages 1074-1079

  Bezard, Erwan ^a,b,c,d,e   Pioli, Elsa Y ^a   Li, Qin ^a,e   Girard, Françoise ^f   Mutel, Vincent ^f   Keywood, Charlotte ^f   Tison, Francois ^b,c,d   Rascol, Olivier ^g,h,i   Poli, Sonia M ^f  

^a Williams House   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^f ADDEX PHARMACEUTICALS   (Switzerland)

^g CIC Toulouse   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Chorea; Dystonia; Macaque; MPTP; On time

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; DIPRAGLURANT; METABOTROPIC RECEPTOR 5; 6-FLUORO-2-(4-(PYRIDIN-2-YL)BUT-3-YN-1-YL)IMIDAZO(1,2-A)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; IMIDAZOLE DERIVATIVE; LEVODOPA; PYRIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DYSKINESIA; GOLD STANDARD; LEVODOPA INDUCED DYSKINESIA; MACAQUE MODEL; MALE; MAXIMUM PLASMA CONCENTRATION; MONKEY MODEL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; SEVERITY OF ILLNESS INDEX; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; IMIDAZOLES; LEVODOPA; MACACA MULATTA; MALE; MOTOR ACTIVITY; MPTP POISONING; PYRIDINES; RECEPTOR, METABOTROPIC GLUTAMATE 5; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84904395573     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25920     Document Type: Article

References (29)

1. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
2. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956-963.
3. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010;39:352-361.
4. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 2006;69:318-326.
5. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008;29:161-168.
6. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007;101:483-497.
7. Yamamoto N, Soghomonian JJ. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 2009;163:1171-1180.
8. Gregoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011;17:270-276.
9. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010;333:865-873.
10. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010;58:981-986.
11. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
12. Ahmed M, Berthet A, Bychkov E, et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2010;2:28ra28.
13. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
14. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
15. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
16. Fasano S, Bezard E, D'Antoni A, et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 2010;107:21824-21829.
17. Ahmed MR, Berthet A, Bychkov E, et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2010;2:28ra28.
18. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signalling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
19. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
20. Fasano S, Bezard E, D'Antoni A, et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 2010;107:21824-21829.
21. Porras G, Berthet A, Dehay B, et al. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 2012;122:3977-3989.
22. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-3394.
23. Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord 2012;27:1373-1378.
24. Testa CM, Standaert DG, Young AB, Penney JB, Jr. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 1994;14:3005-3018.
25. Gubellini P, Pisani A, Centonze D, Bernardi G, Calabresi P. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 2004;74:271-300.
26. Konradi C, Westin JE, Carta M, et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 2004;17:219-236.
27. Ouattara B, Gregoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011;32:1286-1295.
28. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009;330:227-235.
29. Breysse N, Amalric M, Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 2003;23:8302-8309.